146 related articles for article (PubMed ID: 16398152)
1. [Analysis of paraoxonase activity and lipid profile in lupus patients].
Kiss E; Seres I; Zsolt K; Tarr T; Csípo I; Szegedi G; Paragh G
Orv Hetil; 2005 Nov; 146(47):2395-402. PubMed ID: 16398152
[TBL] [Abstract][Full Text] [Related]
2. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.
Kiss E; Seres I; Tarr T; Kocsis Z; Szegedi G; Paragh G
Ann N Y Acad Sci; 2007 Jun; 1108():83-91. PubMed ID: 17893973
[TBL] [Abstract][Full Text] [Related]
3. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
4. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet.
Schulpis KH; Bartzeliotou A; Tsakiris S; Gounaris A; Papassotiriou I
Eur J Clin Nutr; 2007 Jun; 61(6):803-8. PubMed ID: 17203019
[TBL] [Abstract][Full Text] [Related]
5. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
6. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
[TBL] [Abstract][Full Text] [Related]
7. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder.
Sarandol A; Sarandol E; Eker SS; Karaagac EU; Hizli BZ; Dirican M; Kirli S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1103-8. PubMed ID: 16716479
[TBL] [Abstract][Full Text] [Related]
8. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
[TBL] [Abstract][Full Text] [Related]
9. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women.
Kumru S; Aydin S; Gursu MF; Ozcan Z
Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):177-81. PubMed ID: 15140512
[TBL] [Abstract][Full Text] [Related]
10. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia.
Paragh G; Balla P; Katona E; Seres I; Egerházi A; Degrell I
Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):63-7. PubMed ID: 12111338
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.
Chung CP; Oeser A; Solus J; Avalos I; Gebretsadik T; Shintani A; Linton MF; Fazio S; Stein CM
J Rheumatol; 2007 Sep; 34(9):1849-54. PubMed ID: 17659756
[TBL] [Abstract][Full Text] [Related]
12. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study.
Juretić D; Tadijanović M; Rekić B; Simeon-Rudolf V; Reiner E; Baricić M
Croat Med J; 2001 Apr; 42(2):146-50. PubMed ID: 11259735
[TBL] [Abstract][Full Text] [Related]
13. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?
Karp I; Abrahamowicz M; Fortin PR; Pilote L; Neville C; Pineau CA; Esdaile JM
Arthritis Rheum; 2008 Feb; 59(2):169-75. PubMed ID: 18240259
[TBL] [Abstract][Full Text] [Related]
14. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
15. Paraoxonase and arylesterase activities in coronary artery disease.
Gur M; Aslan M; Yildiz A; Demirbag R; Yilmaz R; Selek S; Erel O; Ozdogru I
Eur J Clin Invest; 2006 Nov; 36(11):779-87. PubMed ID: 17032345
[TBL] [Abstract][Full Text] [Related]
16. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients.
Yildiz A; Gur M; Demirbag R; Yilmaz R; Akyol S; Aslan M; Erel O
Clin Biochem; 2008 Jul; 41(10-11):779-84. PubMed ID: 18355454
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus.
Sarkissian T; Beyene J; Feldman B; McCrindle B; Silverman ED
Arthritis Rheum; 2007 Feb; 56(2):631-8. PubMed ID: 17265498
[TBL] [Abstract][Full Text] [Related]
18. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients.
Kiss E; Soltesz P; Der H; Kocsis Z; Tarr T; Bhattoa H; Shoenfeld Y; Szegedi G
J Autoimmun; 2006 Dec; 27(4):211-7. PubMed ID: 17088047
[TBL] [Abstract][Full Text] [Related]
19. [Lipid profile in patients with systemic lupus erythematosus, with special focus on lipoprotein(a) in lupus nephritis].
Kiss E; Fazekas B; Tarr T; Muszbek L; Zeher M; Szegedi G
Orv Hetil; 2004 Feb; 145(5):217-22. PubMed ID: 15024932
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
Bahrehmand F; Vaisi-Raygani A; Rahimi Z; Ahmadi R; Kiani A; Tavilani H; Vaisi-Raygani H; Pourmotabbed T
Lupus; 2014 Mar; 23(3):263-72. PubMed ID: 24399815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
